Omnicell’s fourth quarter was met with a significant negative market reaction, as the company delivered revenue in line with Wall Street expectations but posted a notable shortfall in non-GAAP profitability. Management attributed the quarter’s performance to robust demand for its point-of-care connected devices, particularly the XT S10, and highlighted strong annual recurring revenue momentum. However, mix shifts in product and customer base, as well as higher operating costs tied to new product introductions and customer experience initiatives, weighed on margins. CFO Baird Radford acknowledged that “non-GAAP EBITDA was at the lower end of our guidance,” citing deliberate investments in sales force expansion and innovation.
Is now the time to buy OMCL? Find out in our full research report (it’s free for active Edge members).
Omnicell (OMCL) Q4 CY2025 Highlights:
- Revenue: $314 million vs analyst estimates of $314.2 million (2.3% year-on-year growth, in line)
- Adjusted EPS: $0.40 vs analyst expectations of $0.50 (19.4% miss)
- Adjusted EBITDA: $36.79 million vs analyst estimates of $41.13 million (11.7% margin, 10.5% miss)
- Revenue Guidance for Q1 CY2026 is $305 million at the midpoint, above analyst estimates of $281.8 million
- Adjusted EPS guidance for the upcoming financial year 2026 is $1.75 at the midpoint, missing analyst estimates by 7%
- EBITDA guidance for the upcoming financial year 2026 is $152.5 million at the midpoint, below analyst estimates of $157.2 million
- Operating Margin: 0.1%, down from 4% in the same quarter last year
- Market Capitalization: $1.70 billion
While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.
Our Top 5 Analyst Questions From Omnicell’s Q4 Earnings Call
- Deb (Bank of America) asked about the expected ramp of the Titan XT refresh cycle. CFO Baird Radford explained the opportunity exceeds $2.5 billion and expects an eight-year rollout, while CEO Randall Lipps emphasized customer enthusiasm for the platform’s broader capabilities.
- Matthew Hewitt (Craig Hallum) questioned how existing XT Xtend customers are responding to the Titan XT launch. COO Nnamdi Njoku clarified that XT Xtend consoles will be compatible with Omnisphere, allowing a path to cloud adoption without invalidating recent investments.
- Scott Schoenhaus (KeyBanc) probed the impact of competitive dynamics and Omnicell’s ability to take market share. Lipps highlighted timing advantages and a robust competitive pipeline, while Radford noted guidance assumes only a modest step up in competitive conversions.
- Jessica Tassan (Piper Sandler) inquired about the impact of lease structures on competitive conversions and whether AI tools could pose a threat to Omnicell’s platform. Lipps said Omnicell’s new financing options improve competitiveness, and that Omnisphere is designed to be AI-ready, supporting both Omnicell and third-party tools.
- Stanislav Berenshteyn (Wells Fargo Securities) asked about the mix of robotics revenue and performance of EnlivenHealth and 340B businesses. Njoku reported robotics remains a small contributor, with specialty services steady, but acknowledged ongoing retail headwinds for EnlivenHealth.
Catalysts in Upcoming Quarters
Looking forward, the StockStory team will be watching (1) early demand and implementation pace for Titan XT and Omnisphere, (2) the company’s ability to offset rising tariff and investment costs through supply chain optimization and margin management, and (3) progress in growing annual recurring revenue as more customers shift to cloud-based software subscriptions. We will also track how Omnicell executes its ERP system upgrade and manages its hardware-to-software business model transition.
Omnicell currently trades at $37.34, down from $46.69 just before the earnings. In the wake of this quarter, is it a buy or sell? Find out in our full research report (it’s free).
The Best Stocks for High-Quality Investors
If your portfolio success hinges on just 4 stocks, your wealth is built on fragile ground. You have a small window to secure high-quality assets before the market widens and these prices disappear.
Don’t wait for the next volatility shock. Check out our Top 5 Growth Stocks for this month. This is a curated list of our High Quality stocks that have generated a market-beating return of 244% over the last five years (as of June 30, 2025).
Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+354% five-year return). Find your next big winner with StockStory today.
